The Pleiotropic Effects of HMG-CoA Reductase Inhibitors
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 63 (2) , 139-152
- https://doi.org/10.2165/00003495-200363020-00002
Abstract
HMG-CoA reductase is the rate-limiting enzyme for cholesterol synthesis and its inhibition exerts profound effects on cellular metabolism. Inhibitors of this enzyme are used in clinical practice to...Keywords
This publication has 99 references indexed in Scilit:
- Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytesAtherosclerosis, 2002
- Untangling vascular dementiaThe Lancet, 2001
- Cholesterol, a modulator of membrane-associated aβ-fibrillogenesis and neurotoxicityJournal of Molecular Biology, 2001
- Cholesterol-dependent Formation of GM1 Ganglioside-bound Amyloid β-Protein, an Endogenous Seed for Alzheimer AmyloidJournal of Biological Chemistry, 2001
- Compactin and Simvastatin, but Not Pravastatin, Induce Bone Morphogenetic Protein-2 in Human Osteosarcoma CellsBiochemical and Biophysical Research Communications, 2000
- The design of a prospective study of pravastatin in the elderly at risk (PROSPER)The American Journal of Cardiology, 1999
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Hydroxypropyl-β-cyclodextrin-mediated Efflux of 7-Ketocholesterol from Macrophage Foam CellsJournal of Biological Chemistry, 1996
- Clinical Pharmacokinetics of PravastatinClinical Pharmacokinetics, 1994
- Regulation of the mevalonate pathwayNature, 1990